Track topics on Twitter Track topics that are important to you
Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.
Original Article: Bayer, Janssen’s Xarelto cuts risk of amputation, deathNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...